Today, we are proud to share with you a project that has been in the making for several months. MECP2 Global Duplication (MDG)
The time has come! We are inviting all MDS families to join REMEDS, the REgistre et
Research into MECP2 duplication syndrome has reached an unprecedented milestone: the entry into the world of
The UMass Chan School of Medicine has granted a licence for a promising siRNA-based technology to M2DS, an
Earlier this year, Alvin Luk took part in the CRISPR Medicine conference in Copenhagen to present the latest developments in CRISPR.
Research into the MECP2 gene duplication syndrome has reached an unprecedented stage: it has entered into
The ATTUNE study is a phase 1/2 clinical trial sponsored by Ionis. Its aim is to evaluate ION440, an experimental drug
The HERO clinical trial is a pioneering study evaluating HG204, a new CRISPR Cas13 RNA editing therapy, for the treatment of
We are pleased to share with you two valuable resources that are now online: our series of
In May 2024, Ionis published the ATTUNE study protocol on clinicaltrials.gov. With the aim of providing a better
English (UK) 
Français 
Deutsch 
Español 
Italiano 
Ελληνικά 
Polski